The MEDI4736 study evaluated durvalumab, another anti-PD-L1 Ab, with SOC for primary MGMT unmethylated GBM, and showed OS improvement to 15.7 months, but only when compared with historical controls [62]. The gene discussed is CD274; the disease is glioblastoma.